Your Health, We Care
Release date: 2024-07-10 15:28:38 Article From: Lucius Laos Recommended: 443
LITFULO is a kinase inhibitor used to treat severe alopecia areata in adults and adolescents aged 12 and above. It is not recommended to use in combination with other JAK inhibitors, biological immune modulators, cyclosporin, or other potent immunosuppressants.
In recent years, leveraging the World Trade Organization (WTO) patent waiver for least-developed countries (extended to July 1, 2033), Laos has been legally permitted to produce ge···【more】
Recommended：141Release date: 2026-08-05
How Can Chinese Patients Access Generic Drugs from Laos?In recent years, generic drugs from Laos have gradually entered the view of Chinese cancer and chronic disease patients due ···【more】
Recommended：143Release date: 2026-08-04
Leveraging the WTO patent waiver for least-developed countries (extended to 2033), Laos has seen rapid growth in its generic pharmaceutical industry in recent years. Lucius Pharmac···【more】
Recommended：196Release date: 2026-07-31
Lucius Pharmaceutical is a modern pharmaceutical enterprise headquartered in Vientiane, the capital of Laos. The company was established in 2020, with its R&D and operational s···【more】
Recommended：158Release date: 2026-07-28
Lucius Pharmaceuticals Relocates from India to Laos: A Five-Year Development Journey of a Generic Drug CompanyRelocation Background and Strategic ShiftLucius Pharmaceuticals was fo···【more】
Recommended：252Release date: 2026-07-24
In recent years, Laos has gradually become a major global supply source for generic drugs, leveraging the WTO-granted patent exemption for least-developed countries. Among them, Lu···【more】
Recommended：198Release date: 2026-07-22
Company Overview: Industrial Migration from India to LaosLucius Pharmaceuticals (Laos) Co., Ltd. was established in 2020, with its headquarters located at No. 26, Thongmang Village···【more】
Recommended：211Release date: 2026-07-20
Lucius Pharmaceutical is one of the representative generic drug enterprises in Laos. The company was established in Vientiane, the capital of Laos, in 2020 and has been in operatio···【more】
Recommended：227Release date: 2026-07-17
Industrial Rise: From Zero to a "World Pharmacy" CandidateThe explosive growth of Laos' generic drug industry is rooted in unique international rule dividends. As a U···【more】
Recommended：349Release date: 2026-07-16
In recent years, Laos generic drugs have gradually come into view of oncology and chronic disease patients in China due to their significant price advantage. Leveraging the WTO pat···【more】
Recommended：197Release date: 2026-07-15
Regulatory System: From "One Ministry, One Department" to Legal AmendmentsLao drug regulation adopts a centralized "one ministry, one department" management mod···【more】
Recommended：260Release date: 2026-07-14
Overview of Lao generic drug industryThe Lao generic drug industry started late but has developed rapidly in recent years. Relying on the WTO's patent waiver for least develope···【more】
Recommended：269Release date: 2026-07-09
Dr. Louis, a microbiologist at the World Health Organization (WHO), recently made a technical visit to Lucius Pharmaceuticals in Laos. The purpose of the visit was to learn more ab···【more】
Recommended：894Release date: 2024-07-09
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and mortality, which has been troubling medical workers. Clinical studies have foun···【more】
Recommended：841Release date: 2024-07-09
Lucius Pharmaceuticals Version of Vibegron Now Available1.Basic Drug InformationVibegron (generic name: vibegron) is an oral, once-daily β3-adrenergic receptor agonist approved by ···【more】
Recommended：125Release date: 2026-08-06
Lucius Pharmaceuticals version of Ibrutinib is now availableIn a randomized controlled trial of 269 previously untreated CLL/SLL patients aged 65 years and older, ibrutinib demonst···【more】
Recommended：118Release date: 2026-08-03
Alectinib Has Been Launched in LaosAlectinib is an oral targeted therapeutic drug belonging to the class of ALK inhibitors. Unlike traditional chemotherapy, it does not act by kill···【more】
Recommended：122Release date: 2026-07-30
Lucius Pharmaceuticals Quizartinib (Quizartinib) Has Been Launched(1) Quizartinib is an oral tablet. The recommended dose is once daily, one tablet per day (the specific dose is de···【more】
Recommended：145Release date: 2026-07-29
Lucius version of Dacomitinib is now availableCutaneous adverse reactions and management strategies for DacomitinibRash and exfoliative skin reactions are highly characteristic adv···【more】
Recommended：164Release date: 2026-07-21
Lao PDR: Filgotinib Has Been LaunchedBefore initiating filgotinib treatment, strict screening for the following contraindications is mandatory; the presence of any one of these con···【more】
Recommended：170Release date: 2026-07-13
Lucius Pharmaceuticals' Pirtobrutinib Has Been LaunchedPirtobrutinib is an oral anticancer drug whose active ingredient is pirtobrutinib, belonging to the class of Bruton's···【more】
Recommended：195Release date: 2026-07-10
Lucius Pharmaceuticals (Lao) Co., Ltd. has launched a generic version of elagolix sodium (trade name LuciElag) for the treatment of moderate to severe pain associated with endometr···【more】
Recommended：216Release date: 2026-07-06
Contraindications for Bempedoic Acid (Nilemdo)Bempedoic acid (Nilemdo) is strictly contraindicated in the following situations: ①hypersensitivity to bempedoic acid or any excipient···【more】
Recommended：195Release date: 2026-07-03
MONDAY, June 15, 2026 — A study published online June 8 in Nature Medicine has found that apitegromab, through its selective inhibition of myostatin, can maintain lean body mass wh···【more】
Recommended：230Release date: 2026-06-24
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durvalumab) in combination with BCG (Bacillus Calmette-Guérin) induction and maintenance regimen has rec···【more】
Recommended：333Release date: 2026-06-01
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alf···【more】
Recommended：654Release date: 2025-12-17
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：[list:visits]2025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：[list:visits]2024-09-07
Lucius Pharmaceuticals Version of Vibegron Now Available1.Basic Drug InformationVibegron (generic na···【more】
Recommended：[list:visits]2026-06-08
In recent years, leveraging the World Trade Organization (WTO) patent waiver for least-developed cou···【more】
Recommended：[list:visits]2026-05-08
How Can Chinese Patients Access Generic Drugs from Laos?In recent years, generic drugs from Laos hav···【more】
Recommended：[list:visits]2026-04-08
Lucius Pharmaceuticals version of Ibrutinib is now availableIn a randomized controlled trial of 269 ···【more】
Recommended：[list:visits]2026-03-08
Leveraging the WTO patent waiver for least-developed countries (extended to 2033), Laos has seen rap···【more】
Recommended：[list:visits]2026-31-07
Alectinib Has Been Launched in LaosAlectinib is an oral targeted therapeutic drug belonging to the c···【more】
Recommended：[list:visits]2026-30-07
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
